ABSTRACT
The recent large outbreaks of Ebola virus disease (EVD) in West Africa and the Democratic Republic of the Congo (DRC) have highlighted the need for rapid diagnostic tests to control this disease. In this study, we clinically evaluated a previously developed immunochromatography-based kit, QuickNaviTM-Ebola. During the 2018 outbreaks in DRC, 928 blood samples from EVD-suspected cases were tested with QuickNaviTM-Ebola and the WHO-approved GeneXpert. The sensitivity and specificity of QuickNaviTM-Ebola, estimated by comparing it to GeneXpert-confirmed cases, were 85% (68/80) and 99.8% (846/848), respectively. These results indicate the practical reliability of QuickNaviTM-Ebola for point-of-care diagnosis of EVD.
Subject(s)
Chromatography, Affinity/methods , Ebolavirus/isolation & purification , Hemorrhagic Fever, Ebola/diagnosis , Democratic Republic of the Congo/epidemiology , Disease Outbreaks , Ebolavirus/genetics , Hemorrhagic Fever, Ebola/virology , Humans , Reagent Kits, Diagnostic , Sensitivity and SpecificityABSTRACT
We have evaluated our new Norovirus rapid detection kit "QuickNavi™-Norovirus2" (Denka Seiken Co., Ltd.). The kit is based on Immunochromatographic method using colored latex particles. In addition to simple preparations giving quick (15 min) results, our newly developed kit enables specimen collection directly from rectum and can also be used with neonatal stool samples, both of which cannot be used with the current version of the kit, "QuickNavi™-Norovirus." Clinical study (stool samples, n=172) shows sensitivity, specificity and accuracy of the test compared to RT-PCR are 92.0%, 98.3%, and 94.2%, respectively. The result also showed good correlation with QuickNavi™-Norovirus. In this study, the new Norovirus rapid detection kit has shown sufficient sensitivity and specificity. Their performance, simple preparation enabling rectal swab samples, and quick results can be useful for day to day clinical practice when diagnosing Norovirus infection.
Subject(s)
Feces/virology , Microbiological Techniques/instrumentation , Norovirus/isolation & purification , Caliciviridae Infections/virology , Chromatography, Affinity , Humans , Infant, Newborn , Sensitivity and SpecificityABSTRACT
Because it is not easy to differentiate Influenza virus (Flu) from RS virus (RSV) just by clinical symptoms, to accurately diagnose those viruses in conjunction with patient's clinical symptoms, rapid diagnostic kits has been used separately for each of those viruses. In our new study, we have developed a new rapid diagnostic kit, QuickNavi™-Flu+RSV. The kit can detect Flu A, Flu B, and RSV antigens with a single sample collection and an assay. Total of 2,873 cases (including nasopharyngeal swabs and nasopharyngeal aspirates specimens) in 2010/2011 and 2011/2012 seasons were evaluated with QuickNavi™-Flu+RSV and a commercially available kit. Sensitivity, specificity, and accuracy of Flu type A, type B, and RSV were above 95% when compared to commercially available kits (QuickNavi™-Flu and QuickNavi™-RSV) and considered to be equivalent to the commercially available kits. In 2011/2012 season, RSV infections increased prior to Flu season and continued during the peak of the Flu season. The kit can contribute to accurate diagnosis of Flu and RSV infections since co-infection cases have also been reported during the 2011/2012 season. QuickNavi™-Flu+RSV is useful for differential diagnosis of respiratory infectious diseases since it can detect Flu type A, type B, and RSV virus antigens with a single sample collection.
Subject(s)
Alphainfluenzavirus/isolation & purification , Betainfluenzavirus/isolation & purification , Microbiological Techniques/instrumentation , Reagent Kits, Diagnostic , Respiratory Syncytial Viruses/isolation & purification , Antigens, Viral/analysis , Diagnosis, Differential , Humans , Influenza, Human/diagnosis , Respiratory Syncytial Virus Infections/diagnosis , Sensitivity and SpecificityABSTRACT
We describe a patient with untreated essential thrombocythemia (ET) who developed microgranular variant of acute promyelocytic leukemia, 9 years after the initial diagnosis of ET. He achieved complete remission (CR) but relapsed 11 months later. After achieving the second CR, he received peripheral stem cell transplantation from his HLA complete-matched sibling. Five months after the transplantation, he relapsed again with meningeal infiltration of leukemic cells. In this paper, we review cases of promyelocytic transformation of myeloproliferative diseases (MPD) other than chronic myeloid leukemia (CML). To our knowledge, this is the first case of promyelocytic transformation of Philadelphia chromosome negative untreated ET, in whom both t(15;17) and PML-RAR alpha fusion were proven.
